Actively Recruiting

Phase 4
Age: 18Years - 65Years
All Genders
NCT07122024

Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment

Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-08-14

414

Participants Needed

1

Research Sites

97 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is an open-label, randomized controlled study. The study plans to enroll 414 subjects with Helicobacter pylori infection, who will be randomly assigned to the experimental group (Keverprazan dual therapy for 10 days or Keverprazan dual therapy for 14 days) or the control group (Rabeprazole quadruple therapy for 14 days) at a ratio of 1:1:1.

CONDITIONS

Official Title

Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 65 years, any gender
  • Confirmed Helicobacter pylori infection diagnosed by 13C-urea breath test, H&E staining, or bacterial culture
  • No prior history of H. pylori eradication therapy
  • Able to independently complete a diary card
  • Understands the trial, agrees to participate voluntarily, and can complete the study with informed consent
Not Eligible

You will not qualify if you...

  • Use of acid-suppressing drugs (PPIs, P-CAB, H2 receptor antagonists) within 2 weeks or antibiotics within 4 weeks prior to enrollment
  • Active peptic ulcer with complications such as bleeding, perforation, obstruction, or cancer
  • History of esophageal or gastric surgery
  • Severe systemic diseases including cardiac, pulmonary, cerebral dysfunction, hepatic or renal impairment, or cancer
  • Allergies or hypersensitivity to study drugs or their excipients
  • Pregnant or breastfeeding females
  • Long-term alcohol abuse or other conditions increasing treatment risk
  • Participation in other studies within 3 months or inability to cooperate with investigators
  • Any other reasons judged by the investigator as unsuitable for participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310009

Actively Recruiting

Loading map...

Research Team

J

JUN YE

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here